Dr. Reddy’s Laboratories’ API manufacturing plant at Miryalaguda, has been audited by the US Food and Drug Administration (USFDA) and the audit has been completed on February 21, 2017. The company has been issued a Form 483 with three observations, which it is addressing.
Earlier, in January, South Korea’s Mezzion, a drug company was seeking damages from Dr. Reddy’s Laboratories in a New Jersey court for committing fraud by hiding significant deficiencies and misrepresenting compliance in its manufacturing practices. The suit stated that Dr. Reddy’s repeatedly represented to Mezzion that it was compliant with FDA regulations, and that it hid its misconduct from Mezzion.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: